Want to see KROS full AI Analyst Report?
Keros Therapeutics (KROS) Income Statement
Keros Therapeutics Income Statement
Last quarter (Q2 2026), Keros Therapeutics's total revenue was $0.00, a decrease of 100.00% from the same quarter last year. In Q2, Keros Therapeutics's net income was $-28.71M. See Keros Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 244.06M | $ 3.55M | $ 151.00K | $ 0.00 | $ 20.10M | |
| $ 242.55M | $ 3.55M | $ 151.00K | $ 0.00 | $ 20.10M | |
| $ 171.93M | $ 214.38M | $ 170.09M | $ 114.79M | $ 76.47M | |
| Depreciation and Amortization | $ 1.51M | $ 1.23M | $ 815.00K | $ 674.00K | $ 378.00K |
| $ 93.41M | $ -185.82M | $ -152.18M | $ -104.00M | $ -56.35M | |
| $ 70.62M | $ -210.83M | $ -169.94M | $ -114.79M | $ -56.37M | |
| $ 21.27M | $ 23.78M | $ 16.95M | $ 10.11M | $ -360.00K | |
| $ 91.90M | $ -187.05M | $ -152.99M | $ -104.68M | $ -56.73M | |
| $ 87.01M | $ -187.35M | $ -152.99M | $ -104.68M | $ -58.74M | |
| Per Share Metrics | |||||
| Basic EPS | $ 2.34 | $ -5.00 | $ -5.20 | $ -4.15 | $ -2.52 |
| Diluted EPS | $ 2.30 | $ -5.00 | $ -5.20 | $ -4.15 | $ -2.52 |
| Weighted Average Shares Outstanding | 37.22M | 37.44M | 29.45M | 25.24M | 23.33M |
| Weighted Average Shares Outstanding (Diluted) | 37.86M | 37.44M | 29.45M | 25.24M | 23.33M |
Currency in USD